Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction .
2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis

NCT00051662

Psoriatic Arthritis

COMPLETED PHASE1

Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients

NCT04079920

Rheumatoid Arthritis

COMPLETED

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

NCT04967950

Psoriatic Arthritis

UNKNOWN PHASE1

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

NCT00482417

Rheumatoid Arthritis

COMPLETED PHASE2

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

NCT06905288

Ankylosing Spondylitis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psoriatic arthritis (PSA) is an autoimmune disease arising from the interply between proinflamatory cytokines

\[1\]and external stimuli in genetically predisposed individuals.\[2\]

* The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.\[3\]
* Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .\[4\] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration\[5\].

Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. \[6\] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors \[7\].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease \[8\] is important for the timely introduction of therapy \[9\].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium \[10\].

* The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium\[11\].
* MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6. It affects the functions of the surrounding immune effector cells in locally thickened intima.\[12\]
* During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 \[13\]. MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA \[14\].

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriatic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

psoriatic arthritis patients group

No interventions assigned to this group

health control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PsA patients (age ≥ 18years) who fulfilled the CASPAR classification criteria\[15\]for psoriatic arthritis

Exclusion Criteria

* PsA patients with

1. infection.
2. bone marrow disorders.
3. other autoimmune diseases.
4. diabetes.
5. hypertention .
6. hyperlipidemia.
7. liver diseases.
8. renal diseases.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes